DIA Biosimilars 2013

Spectrum Pharmaceuticals

Spectrum Pharmaceuticals acquires Talon Therapeutics

Wednesday, July 17, 2013 03:46 PM

Spectrum Pharmaceuticals, a commercial and drug development biotech company with a primary focus in hematology and oncology, will acquire Talon Therapeutics, a biopharmaceutical company based in South San Francisco, Calif.

More... »

Cenduit: Now with Patient Reminders

Spectrum appoints Amgen vet Ken Keller as COO

Thursday, September 13, 2012 08:00 AM

Spectrum Pharmaceuticals, a biotechnology company focused on hematology and oncology, has appointed Ken Keller as executive vice president and COO. Keller will have global responsibility for leading commercial operations, medical and clinical development and pharmaceutical operations.

More... »

CRF Health – eCOA Forum

Spectrum completes acquisition of Allos

Friday, September 7, 2012 10:59 AM

Spectrum Pharmaceuticals (SPPI), an Irvine, Calif.-based biotech focused on hematology and oncology, has completed its acquisition of Allos Therapeutics, a Westminster, Colo.-based developer of small molecule drugs.

More... »

Spectrum extends tender offer for shares of Allos Therapeutics

Tuesday, July 10, 2012 11:31 AM

Spectrum Pharmaceuticals, a biotech with a primary focus in oncology and hematology, has extended the offer period for its tender offer to purchase all of the outstanding shares of common stock of Allos Therapeutics, a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics, for $1.82 per share in cash.

More... »

Spectrum to acquire Allos Therapeutics

Friday, April 6, 2012 10:32 AM

Spectrum Pharmaceuticals, a biotechnology company specializing in oncology and hematology, has signed an agreement to acquire all outstanding shares of Allos Therapeutics, a biopharmaceutical company of anti-cancer therapeutics, for $1.82 per share in cash plus one Contingent Value Right (CVR).

More... »

Spectrum names Steven M. Fruchtman vice president of clinical development

Monday, March 7, 2011 08:58 AM

Spectrum Pharmaceuticals, a biotechnology company focused on oncology, has appointed Steven M. Fruchtman, M.D., vice president of clinical development. Dr. Fruchtman will provide strategic planning and leadership for managing the company’s clinical development of belinostat, ZEVALIN and other pipeline products.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2013 CenterWatch.